<DOC>
	<DOCNO>NCT01213095</DOCNO>
	<brief_summary>The clinical efficacy rituximab , chimeric monoclonal antibody target toward B-cell specific antigen CD20 , initially demonstrated case follicular lymphoma ( FL ) , use antibody extend last year majority subtypes B-cell CD20 positive non-Hodgkin 's lymphoma , promise result thus far . In MZL , small number case report chronicle use rituximab single agent phase II trial combination chemotherapeutic regimen . The result rituximab maintenance phase III trial demonstrate patient FL continue take rituximab monotherapy maintenance therapy respond initial course chemotherapy combine without rituximab experience long progression-free survival duration receive rituximab maintenance therapy . The efficacy maintenance treatment first-line induction treatment R-chemotherapy address international PRIMA ( Primary Rituximab Maintenance ) study , enrol 1,217 patient . The first result eagerly await . Although MZL good prognosis TTP OS FL , classify category indolent lymphoma -characterized frequent relapse prolong survival . According result survey , advanced stage MZL tend indolent disease - characterize prolonged survival frequent relapse . Rituximab appear contribute good response , TTP . Thus , consider maintenance treatment MZL patient , extend response duration .</brief_summary>
	<brief_title>Rituximab Maintenance Therapy Marginal Zone B-cell Lymphoma ( MZL )</brief_title>
	<detailed_description>desire description</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm CD20 positive marginal zone Bcell lymphomas Ann Arbor stage III IV No prior chemotherapy radiotherapy advanced stage MZL Tumor response 8th cycle RCVP CTx ≥ SD ( Stable disease ) Performance status ( ECOG ) ≤ 2 age ≥ 20 At least one bidimensionally measurable lesion ( ) : ≥ 2 cm conventional CT/ ≥ 1 cm spiral CT/ skin lesion ( photograph take ) ≥ 2 cm/ measurable lesion physical examination ≥ 2 cm Adequate renal function : serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) Adequate liver function : Transaminase ( AST/ALT ) &lt; 3 X upper normal value / Bilirubin &lt; 1.5 X upper normal value /Alkaline phosphatase &lt; 5 X upper normal value Adequate BM function : ANC &gt; 1500/uL platelet &gt; 75,000/uL Hemoglobin &gt; 9.0 g/dL unless abnormality due bone marrow involvement lymphoma Informed consent Other subtypes NHL MZL Large cell component &gt; 10 % Tumor response 8th cycle CTx = PD ( Progression disease ) Central nervous system ( CNS ) metastasis Any malignancy within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition i. Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry ii . History significant neurologic psychiatric disorder include dementia seizure iii . Active uncontrolled infection ( viral , bacterial fungal infection ) iv . Other serious medical illness Known hypersensitivity study drug ingredient ( i.e. , hypersensitivity Polysorbate 20 , CHO cell product , recombinant human antibody ) Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>B-Cell</keyword>
	<keyword>Marginal Zone</keyword>
	<keyword>Rituximab</keyword>
</DOC>